ATE537707T1 - Lactobacillus paracasei und gewichtskontrolle - Google Patents

Lactobacillus paracasei und gewichtskontrolle

Info

Publication number
ATE537707T1
ATE537707T1 AT08156353T AT08156353T ATE537707T1 AT E537707 T1 ATE537707 T1 AT E537707T1 AT 08156353 T AT08156353 T AT 08156353T AT 08156353 T AT08156353 T AT 08156353T AT E537707 T1 ATE537707 T1 AT E537707T1
Authority
AT
Austria
Prior art keywords
lactobacillus paracasei
weight control
present
metabolic disorders
relates
Prior art date
Application number
AT08156353T
Other languages
English (en)
Inventor
Yoichi Fukushima
Original Assignee
Nestec Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nestec Sa filed Critical Nestec Sa
Application granted granted Critical
Publication of ATE537707T1 publication Critical patent/ATE537707T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K10/00—Animal feeding-stuffs
    • A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
    • A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
    • A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/733—Fructosans, e.g. inulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Polymers & Plastics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Food Science & Technology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Animal Husbandry (AREA)
  • Nutrition Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT08156353T 2008-05-16 2008-05-16 Lactobacillus paracasei und gewichtskontrolle ATE537707T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08156353A EP2123168B1 (de) 2008-05-16 2008-05-16 Lactobacillus paracasei und Gewichtskontrolle

Publications (1)

Publication Number Publication Date
ATE537707T1 true ATE537707T1 (de) 2012-01-15

Family

ID=39591905

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08156353T ATE537707T1 (de) 2008-05-16 2008-05-16 Lactobacillus paracasei und gewichtskontrolle

Country Status (9)

Country Link
US (1) US20110268702A1 (de)
EP (2) EP2123168B1 (de)
JP (1) JP2011523407A (de)
CN (1) CN102026554B (de)
AT (1) ATE537707T1 (de)
DK (1) DK2123168T3 (de)
ES (1) ES2378839T3 (de)
PT (1) PT2123168E (de)
WO (1) WO2009138448A1 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI123157B (fi) * 2009-05-12 2012-11-30 Valio Oy Probioottien uusi käyttö
CN101703528B (zh) * 2009-11-25 2012-07-04 王立平 一种治疗糖尿病的复合微生物制剂及其制备方法和应用
FR2955774A1 (fr) 2010-02-02 2011-08-05 Aragan Preparation destinee a traiter l'exces ponderal et les desordres associes et applications de ladite preparation
TWI406665B (zh) * 2010-09-01 2013-09-01 Genmont Biotech Inc 益生菌株ｇｍ－０８０用於製備治療心臟發炎與心臟細胞凋亡之醫藥組合物及其用途
CN103156098A (zh) * 2011-12-13 2013-06-19 中国科学院烟台海岸带研究所 一种合生元食品添加剂及其制备方法
JP6067292B2 (ja) * 2012-03-19 2017-01-25 サッポロビール株式会社 セロトニン分泌促進剤
CN104413334A (zh) * 2013-08-30 2015-03-18 深圳华大基因科技有限公司 可食用组合物及其制备方法和用途
KR102240196B1 (ko) * 2014-03-24 2021-04-15 오츠카 세이야쿠 가부시키가이샤 신규한 락토바실러스 파라카세이 균주
KR101709246B1 (ko) * 2014-05-30 2017-02-22 일동후디스 주식회사 다시마 및 복합 유산균을 이용한 항비만용 신바이오틱스 조성물
KR102125548B1 (ko) 2015-02-10 2020-06-24 주식회사 지니스 비만 억제능을 갖는 균주 및 이를 함유하는 약학 조성물
WO2017127272A1 (en) 2016-01-18 2017-07-27 Academia Sinica Beneficial effect of bidens pilosa on fat decrease and muscle increase
JP6813974B2 (ja) * 2016-07-14 2021-01-13 株式会社明治 グレリン分泌促進剤
KR101924048B1 (ko) 2016-08-05 2018-11-30 (주)아마존허브 발효 혼합 식이섬유 유산균 제조방법
CN106343370A (zh) * 2016-08-30 2017-01-25 牛婷婷 一种保健营养品豌豆粉的制备方法
CN106306969A (zh) * 2016-08-30 2017-01-11 牛婷婷 一种保健营养品红豆粉的制备方法
CN106343369A (zh) * 2016-08-30 2017-01-25 牛婷婷 一种保健营养品大豆粉的制备方法
BR112019021036A2 (pt) * 2017-04-06 2020-05-12 Korea Food Research Institute Nova cepa com atividade de reduzir produtos finais de gicação avançada, composição, produto fermentado, método para inibir produtos finais de glicação avançada
TWI651412B (zh) * 2017-11-01 2019-02-21 葡萄王生技股份有限公司 用於改善代謝症候群的新穎副乾酪乳桿菌gks6、其培養基、培養方法、用途、醫藥組合物及可食用組合物
CN109744441A (zh) * 2017-11-02 2019-05-14 健茂生物科技股份有限公司 具抗氧化功能的仙人掌果与红龙果复合发酵饮品的制备工艺
CN111954536A (zh) * 2018-03-23 2020-11-17 森永乳业株式会社 用于预防学龄期及之后的高血糖引起的疾病的婴幼儿用组合物
TWI739078B (zh) * 2018-04-25 2021-09-11 日商曾根農場股份有限公司 脂肪累積抑制用組成物
CN111164201B (zh) * 2018-07-02 2023-09-12 葡萄王生技股份有限公司 用于改善代谢症候群的副干酪乳杆菌gks6、其用途、医药组合物及可食用组合物
JP2019022520A (ja) * 2018-10-19 2019-02-14 株式会社東洋新薬 組成物
CN109924506B (zh) * 2019-03-04 2021-06-04 山东环亿生物科技有限公司 一种具有减肥功能的益生菌组合物及其制备方法和应用
CN111743921B (zh) * 2019-03-29 2022-04-15 百岳特生物技术（上海）有限公司 一种副酪蛋白乳酸杆菌或其代谢产物用于制备促进脂肪酸代谢的组合物的用途
CN110638844A (zh) * 2019-10-22 2020-01-03 江苏恒丰强生物技术有限公司 一种预防宠物2型糖尿病的复合微生态制剂及其应用
KR102537991B1 (ko) * 2020-10-13 2023-05-30 경북대학교 산학협력단 돼지 체중 증가용 조성물 및 이의 용도
TWI797769B (zh) * 2021-10-06 2023-04-01 樂牧生技股份有限公司 副乾酪乳酸桿菌lm-141分離株及其用途
GB202411546D0 (en) * 2024-08-06 2024-09-18 Trakia Univ Probiotic lactic acid bacteria and lipid metabolism
CN119842572B (zh) * 2025-03-19 2025-09-02 慕恩（广州）生物科技有限公司 一种防复胖的乳杆菌科菌株及其产品、组合物及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY115050A (en) * 1995-10-16 2003-03-31 Mead Johnson Nutrition Co Diabetic nutritional product having controlled absorption of carbohydrate
ATE348626T1 (de) * 2000-03-24 2007-01-15 Nestle Sa Milchsäurebakterium zur prävention der bauchfellentzündung
KR100356672B1 (ko) 2001-12-27 2002-10-19 주식회사 바이로박트 신규한 락토바실러스 속 미생물 및 그 용도
US7001756B1 (en) 2004-02-19 2006-02-21 Genmont Biotech Inc. Microorganism strain of GM-020 of Lactobacillus rhamnosus and its use for treating obesity
CN100396770C (zh) 2004-03-19 2008-06-25 景岳生物科技股份有限公司 新的微生物鼠李糖乳杆菌gm-020及其治疗肥胖的用途
PL2805625T5 (pl) * 2005-02-28 2023-03-13 N.V. Nutricia Kompozycja odżywcza z prebiotykami i probiotykami
ITMI20051510A1 (it) 2005-08-02 2007-02-03 Proge Farm Srl Uso di specifici batteri lattici per la preparazione di composizioni iunomodulanti
SE529185C2 (sv) * 2005-10-07 2007-05-22 Arla Foods Amba Användning av probiotiska bakterier för tillverkning av livsmedel eller läkemedel för förhindrande av övervikt
MX2008009726A (es) * 2006-01-27 2009-03-05 Danisco Uso de microorganismos probioticos para el tratamiento y prevencion de la obesidad y trastornos relacionados.

Also Published As

Publication number Publication date
JP2011523407A (ja) 2011-08-11
EP2123168B1 (de) 2011-12-21
US20110268702A1 (en) 2011-11-03
WO2009138448A1 (en) 2009-11-19
EP2123168A1 (de) 2009-11-25
CN102026554A (zh) 2011-04-20
EP2296489A1 (de) 2011-03-23
DK2123168T3 (da) 2012-04-10
CN102026554B (zh) 2013-11-06
ES2378839T3 (es) 2012-04-18
PT2123168E (pt) 2012-03-28

Similar Documents

Publication Publication Date Title
DK2123168T3 (da) Lactobacillus paracasei og vægtkontrol
NO2022013I1 (en) Finerenone and its salts, solvates and solvates of the salts thereof
MX2011008398A (es) Lactobacillus helveticus cncm i-4095 y el control del peso.
IL213168A0 (en) 1,2,4-oxadiazole derivatives and their therapeutic use
WO2008053444A3 (en) Treating a respiratory condition with bifidobacterium
CL2012000487A1 (es) Composicion que comprende bifidobacterium longum baa-999 para tratar y/o prevenir trastornos gi funcionales.
MX2011008399A (es) Lactobacillus rhamnosus ncc4007, una mezcla probiotica y el control del peso.
PT2514436T (pt) Il-22 para utilização no tratamento de distúrbios microbianos
MY155516A (en) Lactobacillus rhamnosus and weight control
SG10201401415QA (en) Substituted 2-acetamido-5-aryl-1,2,4-triazolones and use thereof
IL210589A0 (en) The tuberculosis rv2386c protein, compositions and uses thereof
PL1981516T3 (pl) Zastosowanie mikroorganizmów probiotycznych w leczeniu i zapobieganiu otyłości i pokrewnym zaburzeniom
DE602009000317D1 (de) Harzzusammensetzung, Prepreg und deren Verwendungen
DK2385837T3 (da) Sammensætninger omfattende probiotiske og præbiotiske bestanddele og mineralsalte, med lactoferrin
IL200431A0 (en) 1,4-disubstituted 3-cyano-pyridone derivatives and their use as positive mglur2 -receptor modulators
BRPI0812452A2 (pt) Meio de distribuição com ajustador de dose travável e válvula de uma via
MX2011008400A (es) Lactobacillus rhamnosus cncm i-4096 y el control del peso.
PL2276498T3 (pl) Zastosowanie bakterii probiotycznych do leczenia hiperhomocysteinemii
EP2155705A4 (de) Zusammensetzungen zur regulierung oder modulierung eines quorum-sensings in bakterien, verfahren zur verwendung der verbindungen und verfahren zur regulierung oder modulierung eines quorum-sensings in bakterien
ZA201109086B (en) Prevention and treatment of allergic diarrhoea
PL2266619T3 (pl) Kompozycja farmaceutyczna na bazie środków chroniących wątrobę i środków prebiotycznych, ich wytwarzanie i zastosowanie
IL202523A0 (en) Buspirone for the treatment of mausea and vomiting
ATE531715T1 (de) 1,3-dihydro-2h-pyrroloä3.2-büpyridin-2-onderiva e,deren herstellung und deren therapeutische verwendungen
AP2660A (en) 1,4-Naphthoquinone derivatives and therapeutic usethereof
TH0801004134A (th) Lactobacillus rhamnosus และการควบคุมน้ำหนัก